Chennai Journal

Diffuse Large B-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Novartis AG, GlaxoSmithKline Plc, Johnson and Johnson

 Breaking News
  • No posts were found

Diffuse Large B-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Novartis AG, GlaxoSmithKline Plc, Johnson and Johnson

April 25
15:05 2023
Diffuse Large B-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - Novartis AG, GlaxoSmithKline Plc, Johnson and Johnson
DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma.

DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Diffuse Large B-cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diffuse Large B-cell Lymphoma Market Forecast

 

Some of the key facts of the Diffuse Large B-cell Lymphoma Market Report: 

  • The Diffuse Large B-cell Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In November 2022, Regeneron Pharmaceuticals announced that odronextamab Pivotal Phase II data were accepted for oral presentations at the American Society of Hematology (ASH) 2022. Moreover, the company anticipates the US regulatory submission in FL and DLBCL by 2H 2023
  • According to Cancer Research UK, 45% of non-Hodgkin lymphoma cases in the UK are in females, and 55% are in males (Cancer Research UK, n.d.). Gender also matters in terms of NHL clinical characteristics
  • The total incident cases of Diffuse Large B-cell Lymphoma in the 7MM were assessed to be ~73,590 in 2021, and are expected to increase during the study period (2019–2032). Among the 7MM, the US accounted for the highest incidence cases of Diffuse Large B-cell Lymphoma, followed by EU4 and the UK, and Japan
  • The cases of Diffuse Large B-cell Lymphoma have been divided in four stages as Stage I, II, III, and IV, based on how much of the lymphatic system is involved at the time of diagnosis. Stage IV cases account for the highest number of cases, with ~11,680 in 2021 in the United States
  • Key Diffuse Large B-cell Lymphoma Companies: Novartis AG, GlaxoSmithKline Plc, Johnson and Johnson, AstraZeneca, Genmab, AbbVie, Roche, Chugai Pharmaceuticals, MorphoSys AG, ICON Clinical Research, Pfizer, Merck Sharp & Dohme LLC, Pharmatech, Millennium Pharmaceuticals, Inc., Celgene, Karyopharm Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and others
  • Key Diffuse Large B-cell Lymphoma Therapies: Calquence (acalabrutinib), Epcoritamab, POLIVY, Rituximab (RTX), Tafasitamab, Epcoritamab, Cyclophosphamide, PF-07901801, Pembrolizumab, bendamustine, VELCADE, Lenalidomide, Selinexor, TQ-B3525, Polatuzumab Vedotin, and others
  • The Diffuse Large B-cell Lymphoma epidemiology based on gender analyzed that Males have higher incident cases of Diffuse Large B-cell Lymphoma as compared to females
  • The Diffuse Large B-cell Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diffuse Large B-cell Lymphoma pipeline products will significantly revolutionize the Diffuse Large B-cell Lymphoma market dynamics.

 

Diffuse Large B-cell Lymphoma Overview

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that develops when B-lymphocytes become abnormal. It arises from the germinal center and post germinal center B-cells. The etiology of DLBCL is complex and multifactorial. DLBCL can arise de-novo or from the transformation of indolent diseases like chronic lymphocytic lymphoma/small lymphocytic lymphoma (so-called Richter’s transformation), follicular lymphoma, and marginal zone lymphoma

 

Get a Free sample for the Diffuse Large B-cell Lymphoma Market Report –

https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

 

Diffuse Large B-cell Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Diffuse Large B-cell Lymphoma Epidemiology Segmentation:

The Diffuse Large B-cell Lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Diffuse Large B-cell Lymphoma
  • Prevalent Cases of Diffuse Large B-cell Lymphoma by severity
  • Gender-specific Prevalence of Diffuse Large B-cell Lymphoma
  • Diagnosed Cases of Episodic and Chronic Diffuse Large B-cell Lymphoma

 

Download the report to understand which factors are driving Diffuse Large B-cell Lymphoma epidemiology trends @ Diffuse Large B-cell Lymphoma Epidemiology Forecast

 

Diffuse Large B-cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diffuse Large B-cell Lymphoma market or expected to get launched during the study period. The analysis covers Diffuse Large B-cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diffuse Large B-cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Diffuse Large B-cell Lymphoma Therapies and Key Companies

  • Calquence (acalabrutinib): AstraZeneca
  • Epcoritamab: Genmab and AbbVie
  • POLIVY: Roche/Chugai Pharmaceuticals

 

Discover more about therapies set to grab major Diffuse Large B-cell Lymphoma market share @ Diffuse Large B-cell Lymphoma Treatment Market

 

Diffuse Large B-cell Lymphoma Market Strengths

  • The incidence of lymphomas has increased in recent years leading to more focus by pharmaceutical firms
  • The understanding of the biology of DLBCL has increased in the last years and has allowed a better understanding of the molecular mechanisms underlying the disease

 

Diffuse Large B-cell Lymphoma Market Opportunities

  • Rituximab dominates the market in front-line settings, and there is still scope for other drugs in these settings with or without rituximab
  • The recent development in artificial intelligence (AI) technology has shown promising results in reducing labor of pathologists and improving diagnostic accuracy, thus improving the market landscape

 

Scope of the Diffuse Large B-cell Lymphoma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Diffuse Large B-cell Lymphoma Companies: Novartis AG, GlaxoSmithKline Plc, Johnson and Johnson, AstraZeneca, Genmab, AbbVie, Roche, Chugai Pharmaceuticals, MorphoSys AG, ICON Clinical Research, Pfizer, Merck Sharp & Dohme LLC, Pharmatech, Millennium Pharmaceuticals, Inc., Celgene, Karyopharm Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and others
  • Key Diffuse Large B-cell Lymphoma Therapies: Calquence (acalabrutinib), Epcoritamab, POLIVY, Rituximab (RTX), Tafasitamab, Epcoritamab, Cyclophosphamide, PF-07901801, Pembrolizumab, bendamustine, VELCADE, Lenalidomide, Selinexor, TQ-B3525, Polatuzumab Vedotin, and others
  • Diffuse Large B-cell Lymphoma Therapeutic Assessment: Diffuse Large B-cell Lymphoma current marketed and Diffuse Large B-cell Lymphoma emerging therapies
  • Diffuse Large B-cell Lymphoma Market Dynamics: Diffuse Large B-cell Lymphoma market drivers and Diffuse Large B-cell Lymphoma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Diffuse Large B-cell Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Diffuse Large B-cell Lymphoma Market Access and Reimbursement 

 

To know more about Diffuse Large B-cell Lymphoma companies working in the treatment market, visit @ Diffuse Large B-cell Lymphoma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Diffuse Large B-cell Lymphoma Market Report Introduction

2. Executive Summary for Diffuse Large B-cell Lymphoma

3. SWOT analysis of Diffuse Large B-cell Lymphoma

4. Diffuse Large B-cell Lymphoma Patient Share (%) Overview at a Glance

5. Diffuse Large B-cell Lymphoma Market Overview at a Glance

6. Diffuse Large B-cell Lymphoma Disease Background and Overview

7. Diffuse Large B-cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Diffuse Large B-cell Lymphoma 

9. Diffuse Large B-cell Lymphoma Current Treatment and Medical Practices

10. Diffuse Large B-cell Lymphoma Unmet Needs

11. Diffuse Large B-cell Lymphoma Emerging Therapies

12. Diffuse Large B-cell Lymphoma Market Outlook

13. Country-Wise Diffuse Large B-cell Lymphoma Market Analysis (2019–2032)

14. Diffuse Large B-cell Lymphoma Market Access and Reimbursement of Therapies

15. Diffuse Large B-cell Lymphoma Market Drivers

16. Diffuse Large B-cell Lymphoma Market Barriers

17.  Diffuse Large B-cell Lymphoma Appendix

18. Diffuse Large B-cell Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services